

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: **US Patent No. 7,105,490**

Issue Date: **September 12, 2006**

Application No. **10/629,649**

Application Filing Date: **July 30, 2003**

Inventor: **Beeley et al**


Docket: 0212-CIP-9

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313

**Request for Certificate of Correction under 37 CFR §§ 1.322 and 1.323**

1. Patentee respectfully requests consideration and entry of the attached Certificate of Correction under 37 CFR §§ 1.322 and 1.323.
2. The errors are editorial in nature and do not change the scope of the claims.
3. Some errors were caused by the PTO and some errors were caused by the Patentee. In view thereof, the Commissioner is authorized to charge the fee of \$100 to Deposit Account No. 010535.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

  
Edward D. Grieff  
Registration No. 38,898

Date: September 23, 2008  
AMYLIN PHARMACEUTICALS, INC.  
9360 Town Centre Drive  
San Diego, CA 92121  
Phone: 858-552-2200

---

CERTIFICATE OF TRANSMITTAL UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being electronically filed via EFS-Web at the United States Patent and Trademark Office, on the date shown below.

September 23, 2008  
Date of Deposit

  
Marutzella Castro

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,105,490

APPLICATION NO.: 10/629,649

ISSUE DATE : September 12, 2006

INVENTOR(S) : Beeley et al

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 185, Line 32, change "is symptom" to the correct --is a symptom--

Column 185, Line 37, change "or exendin" to the correct --or an exendin--

Column 185, Line 67, change "to o subject" to the correct --to a subject--

Column 187, Line 20, change "pepude" to the correct --peptide--

Column 187, Line 23, change "exeridin-4 acid" to the correct --exendin-4 acid--

### MAILING ADDRESS OF SENDER (Please do not use customer number below):

Amylin Pharmaceuticals, Inc.  
Intellectual Property Department  
9360 Towne Center Drive, San Diego CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*